In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae

Research output: Contribution to journalArticle

Abstract

The in vitro activities of azithromycin (CP-62,993; Pfizer), erythromycin, and tetracycline were evaluated by inhibiting Chlamydia trachomatis and Chlamydia pneumoniae, formerly TWAR, propagation in vitro in McCoy cells, HeLa cells, and HL cells. Eleven clinical isolates of C. trachomatis (serovars D, E, F, J, K, and L2) and four strains of C. pneumoniae were tested with an inoculum of 103 inclusion-forming units in a 96-well microtiter plate. The MIC ranges of these antimicrobial agents against C. trachomatis were as follows: azithromycin, 0.125 to 0.5 μg/ml; erythromycin, 0.25 to 0.1 μg/ml; and tetracycline, 0.0625 to 1.0 μg/ml. The MBC ranges, calculated from passage into antibiotic-free medium, were as follows: azithromycin, 0.125 to 4.0 μg/ml; erythromycin, 0.5 to 8.0 μg/ml; and tetracycline, 0.0625 to 4.0 μg/ml. The MIC ranges for C. pneumoniae in both HeLa and HL cells were as follows: azithromycin, 0.125 to 1.0 μg/ml; erythromycin, 0.0625 to 1.0 μg/ml; and tetracycline, 0.125 to 1.0 μg/ml. The MBC ranges were as follows: azithromycin, 0.25 to 1.0 μg/ml; erythromycin, 0.25 to 1.0 μg/ml; and tetracycline, 0.125 to 4.0 μg/ml. From the results of this in vitro study, azithromycin appears to be an effective antibiotic comparable to tetracycline and erythromycin for use in the treatment of both C. trachomatis and C. pneumoniae infections.

Original languageEnglish (US)
Pages (from-to)291-294
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number2
StatePublished - 1992

Fingerprint

Chlamydophila pneumoniae
Azithromycin
Chlamydia trachomatis
Erythromycin
Tetracycline
HeLa Cells
Anti-Bacterial Agents
Chlamydia Infections
Anti-Infective Agents
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{b0aea8f26cfe4155a9280bfb7c71e8aa,
title = "In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae",
abstract = "The in vitro activities of azithromycin (CP-62,993; Pfizer), erythromycin, and tetracycline were evaluated by inhibiting Chlamydia trachomatis and Chlamydia pneumoniae, formerly TWAR, propagation in vitro in McCoy cells, HeLa cells, and HL cells. Eleven clinical isolates of C. trachomatis (serovars D, E, F, J, K, and L2) and four strains of C. pneumoniae were tested with an inoculum of 103 inclusion-forming units in a 96-well microtiter plate. The MIC ranges of these antimicrobial agents against C. trachomatis were as follows: azithromycin, 0.125 to 0.5 μg/ml; erythromycin, 0.25 to 0.1 μg/ml; and tetracycline, 0.0625 to 1.0 μg/ml. The MBC ranges, calculated from passage into antibiotic-free medium, were as follows: azithromycin, 0.125 to 4.0 μg/ml; erythromycin, 0.5 to 8.0 μg/ml; and tetracycline, 0.0625 to 4.0 μg/ml. The MIC ranges for C. pneumoniae in both HeLa and HL cells were as follows: azithromycin, 0.125 to 1.0 μg/ml; erythromycin, 0.0625 to 1.0 μg/ml; and tetracycline, 0.125 to 1.0 μg/ml. The MBC ranges were as follows: azithromycin, 0.25 to 1.0 μg/ml; erythromycin, 0.25 to 1.0 μg/ml; and tetracycline, 0.125 to 4.0 μg/ml. From the results of this in vitro study, azithromycin appears to be an effective antibiotic comparable to tetracycline and erythromycin for use in the treatment of both C. trachomatis and C. pneumoniae infections.",
author = "Welsh, {L. E.} and Gaydos, {Charlotte A} and Quinn, {Thomas C}",
year = "1992",
language = "English (US)",
volume = "36",
pages = "291--294",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae

AU - Welsh, L. E.

AU - Gaydos, Charlotte A

AU - Quinn, Thomas C

PY - 1992

Y1 - 1992

N2 - The in vitro activities of azithromycin (CP-62,993; Pfizer), erythromycin, and tetracycline were evaluated by inhibiting Chlamydia trachomatis and Chlamydia pneumoniae, formerly TWAR, propagation in vitro in McCoy cells, HeLa cells, and HL cells. Eleven clinical isolates of C. trachomatis (serovars D, E, F, J, K, and L2) and four strains of C. pneumoniae were tested with an inoculum of 103 inclusion-forming units in a 96-well microtiter plate. The MIC ranges of these antimicrobial agents against C. trachomatis were as follows: azithromycin, 0.125 to 0.5 μg/ml; erythromycin, 0.25 to 0.1 μg/ml; and tetracycline, 0.0625 to 1.0 μg/ml. The MBC ranges, calculated from passage into antibiotic-free medium, were as follows: azithromycin, 0.125 to 4.0 μg/ml; erythromycin, 0.5 to 8.0 μg/ml; and tetracycline, 0.0625 to 4.0 μg/ml. The MIC ranges for C. pneumoniae in both HeLa and HL cells were as follows: azithromycin, 0.125 to 1.0 μg/ml; erythromycin, 0.0625 to 1.0 μg/ml; and tetracycline, 0.125 to 1.0 μg/ml. The MBC ranges were as follows: azithromycin, 0.25 to 1.0 μg/ml; erythromycin, 0.25 to 1.0 μg/ml; and tetracycline, 0.125 to 4.0 μg/ml. From the results of this in vitro study, azithromycin appears to be an effective antibiotic comparable to tetracycline and erythromycin for use in the treatment of both C. trachomatis and C. pneumoniae infections.

AB - The in vitro activities of azithromycin (CP-62,993; Pfizer), erythromycin, and tetracycline were evaluated by inhibiting Chlamydia trachomatis and Chlamydia pneumoniae, formerly TWAR, propagation in vitro in McCoy cells, HeLa cells, and HL cells. Eleven clinical isolates of C. trachomatis (serovars D, E, F, J, K, and L2) and four strains of C. pneumoniae were tested with an inoculum of 103 inclusion-forming units in a 96-well microtiter plate. The MIC ranges of these antimicrobial agents against C. trachomatis were as follows: azithromycin, 0.125 to 0.5 μg/ml; erythromycin, 0.25 to 0.1 μg/ml; and tetracycline, 0.0625 to 1.0 μg/ml. The MBC ranges, calculated from passage into antibiotic-free medium, were as follows: azithromycin, 0.125 to 4.0 μg/ml; erythromycin, 0.5 to 8.0 μg/ml; and tetracycline, 0.0625 to 4.0 μg/ml. The MIC ranges for C. pneumoniae in both HeLa and HL cells were as follows: azithromycin, 0.125 to 1.0 μg/ml; erythromycin, 0.0625 to 1.0 μg/ml; and tetracycline, 0.125 to 1.0 μg/ml. The MBC ranges were as follows: azithromycin, 0.25 to 1.0 μg/ml; erythromycin, 0.25 to 1.0 μg/ml; and tetracycline, 0.125 to 4.0 μg/ml. From the results of this in vitro study, azithromycin appears to be an effective antibiotic comparable to tetracycline and erythromycin for use in the treatment of both C. trachomatis and C. pneumoniae infections.

UR - http://www.scopus.com/inward/record.url?scp=0026502163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026502163&partnerID=8YFLogxK

M3 - Article

C2 - 1318677

AN - SCOPUS:0026502163

VL - 36

SP - 291

EP - 294

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -